An update on the drug safety of treating erectile dysfunction

Basit Öğe Kaydı
dc.authorid0000-0002-2530-7012
dc.contributor.authorGül, Murat
dc.contributor.authorŞerefoğlu, Ege Can
dc.date.accessioned2019-12-30T05:51:14Z
dc.date.available2019-12-30T05:51:14Z
dc.date.issued2019
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Histoloji ve Embriyoloji Ana Bilim Dalı
dc.description.abstractIntroduction: Treatment options for erectile dysfunction (ED) have evolved over the last two decades, particularly after the introduction of phosphodiesterase type-5 inhibitors (PDE5Is). The path, however, has not been straightforward with issues raised regarding safety and toxicity following ED treatments. Areas covered: A literature review was conducted on current evidence related to the safety of PDE5Is, intracavernosal injections and various older forms of oral therapies. Relevant trials were identified through a literature search of PubMed from 1980 to 2019. Expert opinion: PDE5Is are now recommended as the first line therapy for the treatment of ED due to their efficacy and tolerable side effects. Comparison of the various PDE5Is on safety has not been supported by prime evidence, and consequently, the negative aspects of each inhibitor appear the same as defined in the literature. Other means of therapies for ED are still in the running, and these also present a different range of side effects. While intracavernosal injections have potential to cause priapism and penile fibrosis, intraurethral alprostadil may result in more systematic side effects. Alternative topical ED therapies are generally limited with their local side effects.
dc.identifier.citationGül, M. ve Şerefoğlu, E. C. (2019). An update on the drug safety of treating erectile dysfunction. Expert Opinion On Drug Safety, 18(10), 965-975. https://doi.org/10.1080/14740338.2019.1659244
dc.identifier.doi10.1080/14740338.2019.1659244
dc.identifier.endpage975
dc.identifier.issn1474-0338
dc.identifier.issn1744-764X
dc.identifier.issue10
dc.identifier.scopusqualityQ1
dc.identifier.startpage965
dc.identifier.urihttps://doi.org/10.1080/14740338.2019.1659244
dc.identifier.urihttps://hdl.handle.net/20.500.12511/4789
dc.identifier.volume18
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis
dc.relation.ispartofExpert Opinion On Drug Safetyen_US
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAdverse Effects
dc.subjectAlprostadil
dc.subjectErectile Dysfunction
dc.subjectPhosphodiesterase Type 5 Inhibitors
dc.subjectProstaglandin E1
dc.subjectSafety
dc.titleAn update on the drug safety of treating erectile dysfunction
dc.typeOther

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Diğer Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu